Novogen, a biotechnology company, has announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology. ATM drugs represent an entirely novel approach to anti-cancer therapy, blocking the ...
Celgene International's oral anti-cancer therapy Pomalidomide has won European Commission approval as treatment for patients with relapsed/refractory multiple myeloma (rrMM), a rare form of blood cancer, in combination with dexamethasone. ...
Tags: Anti-Cancer Therapy
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Celgene International's oral anti-cancer therapy Pomalidomide. The positive results from the MM-003 study of ...